Skip to main content
CNTB logo

Connect Biopharma Holdings Limited

CNTBNASDAQHealthcareBiotechnology

$0.91Today:- (-)1Y −50.48%

As of Oct 15, 2026 close

Market cap
$56.99M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$0.85$3.82
Volume (live)
-
Avg. volume (3M)
7.58M

Connect Biopharma Holdings (CNTB) Income Statement

Connect Biopharma Holdings reported revenue of $64.00K in fiscal 2025 (fiscal year ended Mar 31, 2026), down 99.8% from $26.03M a year earlier. Connect Biopharma Holdings posted a net loss of $55.48M, compared with a net loss of $15.63M a year earlier. Gross margin was 100.0% and operating margin -90740.6%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $2.77M, up 5666.7% from the same quarter a year earlier.

Connect Biopharma Holdings Income Statement Analysis

Values in millions USD

Scroll to see more
Connect Biopharma Holdings Limited income statement - Annual data in millions USD
BreakdownFY 2025FY 2025FY 2024FY 2024FY 2023FY 2022FY 2021FY 2021FY 2021FY 2020FY 2019
Period endingMar 2026Dec 2025Mar 2025Dec 2024Dec 2023Dec 2022Mar 2022Jan 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue0.060.0626.0326.030.000.000.00--0.000.00
Cost of Revenue0.00-0.00-0.000.000.00--0.000.00
Gross Profit0.060.0626.0326.030.000.000.00--0.000.00
Operating Expenses
Research & Development37.8037.8029.2627.8653.0096.6380.5080.5080.5023.1215.44
Selling, General & Administrative20.3420.3419.2317.4316.0520.8119.0119.0119.017.311.41
Operating Expenses58.1458.1448.4945.2969.06116.5198.1197.6696.5629.3616.44
Operating Income-58.07-58.07-22.45-19.25-69.06-116.51-98.11-97.66-96.56-30.30-15.99
Other Income/Expense
Interest Income2.272.274.454.455.221.540.100.170.100.110.15
Interest Expense0.00-0.00-0.000.02--0.010.01-0.44-
Other Income/Expense2.790.527.052.591.85-2.81-103.89-103.98-105.53-89.68-8.17
Income
Income Before Tax-55.28-55.28-15.41-15.41-61.99-117.79-202.00-202.00-202.00-119.37-24.46
Income Tax Expense0.200.200.220.220.120.300.270.270.270.000.00
Net Income-55.48-55.48-15.63-15.63-62.11-118.09-202.27-202.27-202.27-119.37-24.46
Net Income - Continuous Operations-55.48-55.48-15.63-15.63-62.11-118.09-202.27--202.27-119.37-24.46
Net Income - Discontinued Operations-----------
EBITDA-54.58-57.37-14.75-18.59-68.34-116.74-201.36-97.17-201.36-118.21-24.78
EBIT--58.07--19.25-69.06-117.77--97.66-201.99-29.36-
Depreciation & Amortization0.700.700.660.660.721.030.630.490.630.220.11
Earnings Per Share
Basic EPS-1.00-1.00---1.00-2.00-25.00-4.00-4.00-14.00-3.00
Diluted EPS-1.00-1.00---1.00-2.00-25.00-4.00-4.00-14.00-3.00
Basic Shares Outstanding55.6655.6655.2155.2155.0755.0452.2752.1852.2753.9455.82
Diluted Shares Outstanding55.6655.6655.2155.2155.0755.0452.2752.1852.2753.9455.82

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Connect Biopharma Holdings Financial Statements

What was Connect Biopharma Holdings's revenue in fiscal 2025?

Connect Biopharma Holdings reported revenue of $64.00K in fiscal 2025 (fiscal year ended Mar 31, 2026). That was down 99.8% from $26.03M a year earlier.

Is Connect Biopharma Holdings profitable?

No. Connect Biopharma Holdings reported a net loss of $55.48M in fiscal 2025. In fiscal 2024 it lost $15.63M.

What is Connect Biopharma Holdings's operating margin?

Connect Biopharma Holdings's operating income was −$58.07M on revenue of $64.00K in fiscal 2025, an operating margin of -90740.6%, compared with -86.2% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition